



February 10, 2026

Company name: YOMEISHU SEIZO CO., LTD.
Name of representative: Hideo Tanaka,
Representative Director President
Securities code: 2540; TSE Prime Market
For inquiries: Akira Igawa,
Director Senior Executive Officer
General Manager Corporate
Planning Department
Telephone: +81-3-3462-8138

Notice Regarding Participation in a Tender Offer and Expected Recognition of Extraordinary Income

YOMEISHU SEIZO CO., LTD. (the “Company”) hereby announces that, at a meeting of the Board of Directors held today, the Company has decided to participate in a tender offer conducted by TAIYO KOSAN CO.,INC. (the “Tender Offer”) in relation to all of the common stock of Hisamitsu Pharmaceutical Co., Inc. (securities code: 4530) held by the Company. As a result of the Company’s participation in the Tender Offer, the Company expects to record extraordinary income as gains on sale of investment securities for the fiscal year ending March 31, 2026.

1. Reason for participation in the Tender Offer

The Company currently holds shares in Hisamitsu Pharmaceutical Co., Inc. as strategically-held shares. After reviewing the details of the Tender Offer, the Company has decided to participate in the Tender Offer based on elements such as the fact that Company has determined that the participation in the Tender Offer would serve to contribute to the improvement of the Company’s corporate value upon the comprehensive consideration of various factors, which include the fact that the Board of Directors of Hisamitsu Pharmaceutical Co., Inc. has expressed its support for the Tender Offer and the fact that the terms of the Tender Offer (such as the purchase price) can be deemed to be reasonable, based on the reasons for the Board of Directors' decision.

2. Number of shares held to be tendered in the Tender Offer

Number of shares held before tendering	101,000 shares
Number of shares to be tendered	101,000 shares
Number of shares held after tendering	0 shares

3. Expected purchase price in the Tender Offer

6,082 yen per share of common stock (expected total amount of sales: 614 million yen).

4. Schedule of the Tender Offer

Date of public notice of the commencement of the Tender Offer	Wednesday, January 7, 2026
Period of the Tender Offer	Wednesday, January 7, 2026 to Thursday, February 19, 2026
Commencement date of settlement	Friday, February 27, 2026

5. Future outlook

If the Tender Offer is completed at the expected purchase price and all of the Company's holdings of common stock of Hisamitsu Pharmaceutical Co., Inc. are sold, the Company expects to record extraordinary income in the amount of 413 million yen as gains on sale of investment securities for the fiscal year ending March 31, 2026. Please note, however, that there are no changes to be made to current financial results forecasts since the gains on sale of investment securities for strategically-held shares have already been incorporated into the financial figures for the fiscal year ending March 31, 2026.